Ofichem Group, a leading developer, manufacturer, and distributor of active pharmaceutical ingredients (APIs) for both veterinary and human markets, has acquired OT Chemistry for an undisclosed amount. This corporate acquisition sees Ofichem Group expanding its operational footprint and service portfolio in the pharmaceutical sector.
Ofichem Group is well-established for its comprehensive 'Allround in APIs' approach, delivering high-quality, GMP-compliant compounds worldwide to pharmaceutical producers. Its services span contract manufacturing (CMO), research and development (R&D), analytical testing for both internal and external clients, strategic sourcing, and regulatory auditing. The acquisition of OT Chemistry is a strategic move designed to bolster Ofichem Group's existing capabilities and enhance its offering within the complex API supply chain.
This transaction is expected to generate significant synergies, primarily by strengthening Ofichem Group's integrated service model. While specific details about OT Chemistry’s operations were not disclosed, the acquisition is anticipated to complement Ofichem's robust R&D and manufacturing divisions, potentially expanding its capacity for API development and production or broadening its analytical services. The strategic intent is to further solidify Ofichem Group’s position as a versatile partner in providing critical raw materials for safe medicines.
The combination of Ofichem Group's established expertise and the newly integrated capabilities from OT Chemistry is poised to enhance the combined entity's ability to meet diverse client requirements globally. The focus remains on maintaining high standards of quality and safety in pharmaceutical raw materials, crucial for improving human and animal health.